Business
INmune Bio, Inc. Announces First Alzheimer’s Disease Patient Dosed in XPro1595 Study
Neuroinflammation targeted in XPro1595 Phase Ib clinical trial LA JOLLA, Calif., Dec. 02, 2019 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (NASDAQ: INMB), an
About this update from Inmune Bio Inc.
[{"type":"text","content":"Neuroinflammation targeted in XPro1595 Phase Ib clinical trial\n LA JOLLA, Calif., Dec. 02, 2019 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (NASDAQ: INMB), an immunology company developing treatments that harness the patient’s innate immune system to fight disease, announced today the dosing of the first patient in the Phase Ib clinical trial for patients with Alzheimer's disease. The trial is examining the safety and efficacy of INmune Bio’s XPro1595, a next-generation anti-inflammatory drug that selectively neutralizes the “bad” inflammation, soluble tumor necrosis factor (sTNF), which is strongly implicated in Alzheimer's disease. “This is a significant milestone for INmune Bio and for a field desperate for novel approaches to treat approximately 50 million people suffering from Alzheimer’s worldwide,” said C.J. Barnum, Ph.D., Director of Neuroscience at INmune Bio. “XPro1595 targets the dysfunctional immune system that gives rise to chronic neuroinflammation in Alzheimer’s patients. The goal of this Phase Ib study is to demonstrate that XPro1595 is safe and can reduce neuroinflammation.” The announcement comes just a day before INmune Bio’s live webinar taking place on Tuesday, Dec. 3, 2019, from 1:00 p.m. to 2:00 p.m. (EST) and titled, “Bench to Bedside: A Pre-CTAD Webinar Highlighting An Alternative Approach For Alzheimer’s Disease.” As host and moderator, INmune Bio’s Chief Executive Officer, R.J. Tesi, M.D., will be joined by Lawrence T. Friedhoff, M.D., Ph.D., Malú G. Tansey, Ph.D., and Sharon Cohen, M.D., FRCPC. During the webinar, the panelists will discuss alternative approaches and therapeutics and methodological issues important to the development of the next generation of Alzheimer’s disease treatments. Attendees can register for the webinar by visiting https://russopartners.webex.com/russopartners/onstage/g.php?MTID=ea7cacd067c33e65bad04c76504eb28d2 “This approach to fighting one of the most devastating diseases of our time, which differs from current therapies targeting amyloid plaques, could be a key to cracking the code of Alzheimer’s disease,” said Dr. Tesi. “Although the first study is designed to demonstrate safety, we are collecting data that will inform on the potential for XPro1595 as an effective therapy for Alzheimer’s patients.\" “Neuroinflammation is one of the most exciting targets to slow or stop the pro...